论文部分内容阅读
目的探讨多西他赛同步放化疗对中晚期食管癌的近期疗效及不良反应。方法将60例中晚期食管癌患者随机分为多西他赛治疗组和单放组各30例,两组放射治疗均采用常规分割外照射,治疗组在放疗同期每周接受1次多西他赛化疗40mg/周,连用6周。结果治疗组总有效率83.3%,单放组总有效率67.7%,两者差异有统计学意义。1年生存率治疗组76.7%,单放组53.3%,两组间差异有统计学意义。治疗组不良反应可耐受。结论多西他赛同步放疗治疗中晚期食管癌可提高近期疗效,毒副作用较小。
Objective To investigate the short-term curative effect and adverse reactions of docetaxel concurrent chemoradiotherapy on advanced esophageal cancer. Methods Sixty patients with advanced esophageal cancer were randomly divided into three groups: docetaxel group and radix salvia miltiorrhiza group, 30 cases in each group. Conventional radiotherapy was used to radiotherapy in both groups. The radiotherapy group received docetaxel once a week Match chemotherapy 40mg / week, once every 6 weeks. Results The total effective rate was 83.3% in the treatment group and 67.7% in the single operation group, the difference was statistically significant. The 1-year survival rate was 76.7% in the treatment group and 53.3% in the single group, with significant difference between the two groups. Adverse reactions in the treatment group were tolerated. Conclusion Docetaxel concurrent radiotherapy for advanced esophageal cancer can improve the short-term efficacy, with less side effects.